An estrogen receptor (ER)-related signature in predicting prognosis of ER-positive breast cancer following endocrine treatment.

ABSTRACT: Quite a few estrogen receptor (ER)-positive breast cancer patients receiving endocrine therapy are at risk of disease recurrence and death. ER-related genes are involved in the progression and chemoresistance of breast cancer. In this study, we identified an ER-related gene signature that can predict the prognosis of ER-positive breast cancer patient receiving endocrine therapy. We collected RNA expression profiling from Gene Expression Omnibus database. An ER-related signature was developed to separate patients into high-risk and low-risk groups. Patients in the low-risk group had significantly better survival than those in the high-risk group. ROC analysis indicated that this signature exhibited good diagnostic efficiency for the 1-, 3- and 5-year disease-relapse events. Moreover, multiv

SUBMITTER: Tang J 

PROVIDER: S-EPMC6652714 | biostudies-literature | 2019 Aug

REPOSITORIES: biostudies-literature